浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Intervention effect and mechanism of breviscapine on hepatic fibrosis in rats
- ZHONGGUO YAOFANG Vol. 35, Issue 6, Pages: 671-677(2024)
- 作者机构：
1.河南中医药大学第一附属医院针灸疼痛科，郑州 450099
2.河南中医药大学医学院，郑州 450046
3.河南中医药大学第三附属医院肿瘤科，郑州 450006
4.西藏藏医药大学藏医药与高原生物重点实验室，拉萨 850005
5.郑州大学实验动物中心，郑州 450008
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.06.06
CLC： R965;R285.5Published：30 March 2024，
Received：19 August 2023，
Revised：29 December 2023，
扫 描 看 全 文
魏丹丹,李闪闪,张明昊等.灯盏花素对肝纤维化大鼠的干预作用及机制 Δ[J].中国药房,2024,35(06):671-677.
WEI Dandan,LI Shanshan,ZHANG Minghao,et al.Intervention effect and mechanism of breviscapine on hepatic fibrosis in rats[J].ZHONGGUO YAOFANG,2024,35(06):671-677.
魏丹丹,李闪闪,张明昊等.灯盏花素对肝纤维化大鼠的干预作用及机制 Δ[J].中国药房,2024,35(06):671-677. DOI： 10.6039/j.issn.1001-0408.2024.06.06.
WEI Dandan,LI Shanshan,ZHANG Minghao,et al.Intervention effect and mechanism of breviscapine on hepatic fibrosis in rats[J].ZHONGGUO YAOFANG,2024,35(06):671-677. DOI： 10.6039/j.issn.1001-0408.2024.06.06.
摘要
目的
2
基于转化生长因子β
1
（TGF-β
1
）/Smad2/胞外信号调节激酶1（ERK1）通路和Kelch样环氧氯丙烷相关蛋白1（Keap1）/核转录因子红系2相关因子2（Nrf2）/血红素加氧酶1（HO-1）通路，探讨灯盏花素对肝纤维化（HF）大鼠的干预作用及潜在机制。
方法
2
将60只大鼠随机分为正常对照组，模型组，灯盏花素低、中、高剂量组（5.4、10.8、21.6 mg/kg）和秋水仙碱组（阳性对照，0.45 mg/kg），每组10只，雌雄各半。除正常对照组外，其余各组大鼠均以四氯化碳诱导构建HF模型。随后，各药物组大鼠灌胃相应药液，每天1次，连续28 d。观察各组大鼠的肝脏外观并计算其肝脏系数，检测其血清中丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）水平和肝组织中ALT、AST、超氧化物歧化酶（SOD）、丙二醛（MDA）、谷胱甘肽过氧化物酶（GSH-Px）水平，观察其肝组织炎症和纤维化情况，检测肝组织中TGF-β
1
、Smad、ERK1、Nrf2、Keap1、HO-1蛋白及mRNA的表达情况。
结果
2
与正常对照组比较，模型组大鼠肝脏可见大面积的白色结节灶、明显的炎症细胞浸润和胶原纤维沉积；其体重，肝组织中SOD、GSH-Px水平和Nrf2、HO-1蛋白及mRNA的表达水平均显著降低（
P
＜0.05）；肝脏系数，Masson染色阳性面积百分比，血清及肝组织中ALT、AST水平，肝组织中MDA水平和TGF-β
1
、Smad2、ERK1、Keap1蛋白及mRNA的表达水平显著升高（
P
＜0.05）。与模型组比较，各药物组大鼠肝组织病变均有所改善，上述定量指标普遍逆转（
P
＜0.05）。
结论
2
灯盏花素对大鼠HF有较好的干预作用，其作用可能与抑制TGF-β
1
/Smad2/ERK1通路来抗纤维化，调控Keap1/Nrf2/HO-1通路来抑制氧化应激有关。
Abstract
OBJECTIVE
2
To investigate the intervention effect and potential mechanism of breviscapine on hepatic fibrosis （HF） in rats based on the transforming growth factor-β
1
（TGF-β
1
）/Smad2/extracellular signal-regulated protein kinase 1（ERK1） and Kelch-like epichlorohydrin-associated protein 1（Keap1）/nuclear factor-erythroid 2-related factor 2（Nrf2）/heme oxygenase-1（HO-1） pathways.
METHODS
2
Totally 60 rats were randomly divided into normal control group， model group， breviscapine low-dose， medium-dose and high-dose groups （5.4， 10.8， 21.6 mg/kg）， and colchicine group （positive control， 0.45 mg/kg）， with 10 rats in each group， half male and half female. Except for the normal control group， HF model of the other groups was induced by carbon tetrachloride. Subsequently， each drug group was given corresponding medicine by gavage once a day for 28 days. The liver appearance of rats in each group was observed and their liver coefficients were calculated. The levels of alanine aminotransferase （ALT） and aspartate aminotransferase （AST） in serum， those of ALT， AST， superoxide dismutase （SOD）， malondialdehyde （MDA） and glutathione peroxidase （GSH-Px） in liver tissue were detected. The liver tissue inflammatory and fibrotic changes were observed. The protein and mRNA expressions of TGF-β
1
， Smad2， ERK1， Nrf2， Keap1 and HO-1 in liver tissue were detected.
RESULTS
2
Compared with the normal control group， the model group showed large areas of white nodular lesions in the liver， obvious inflammatory cell infiltration and collagen fiber deposition. The body weight， the levels of SOD and GSH-Px in liver tissue， the protein and mRNA expressions of Nrf2 and HO-1 were significantly lowered in the model group （
P
＜0.05）； the liver coefficient， the percentage of Masson staining positive area， ALT and AST levels of serum and liver tissue， MDA level of liver tissue， the protein and mRNA expressions of TGF-β
1
， Smad2， ERK1 and Keap1 were significantly increased （
P
＜0.05）. Compared with the model group， the liver lesions of rats in each drug group were improved， and the above quantitative indexes were generally reversed （
P
＜0.05）.
CONCLUSIONS
2
Breviscapine has a good intervention effect on HF rats， which may be related to inhibiting TGF-β
1
/Smad2/ERK1 pathway for anti-fibrosis and regulating Keap1/Nrf2/HO-1 pathway to inhibit oxidative stress.
关键词
灯盏花素肝纤维化氧化应激转化生长因子β1/Smad2/胞外信号调节激酶1通路Kelch样环氧氯丙烷相关蛋白1/核转录因子红系2相关因子2/血红素加氧酶1通路
Keywords
hepatic fibrosisoxidative stressTGF-β1/Smad2/ERK1 pathwayKeap1/Nrf2/HO-1 pathway
references
张明昊，高一盈，董文霞，等. 丹参多酚酸盐对肝纤维化小鼠Notch-Hes1信号通路的影响[J]. 中国临床药理学杂志，2022，38（9）：949-954.
ZHANG M H，GAO Y Y，DONG W X，et al. Effects of salvianolate on Notch-Hes1 signal pathway in mice with liver fibrosis[J]. Chin J Clin Pharmacol，2022，38（9）：949-954.
巴图德力根，薛兰，牧仁，等. 德都红花-7味散对四氯化碳所致慢性肝损伤大鼠凋亡蛋白表达的影响[J]. 中国临床药理学杂志，2022，38（11）：1215-1218.
Batudeligen，XUE L，MU R，et al. Effect of Deduhonghua-7 powder on expression of apoptotic protein of carbon te-trachloride induced chronic liver injury rats[J]. Chin J Clin Pharmacol，2022，38（11）：1215-1218.
马婷，邝晓岚，蔡婉娜，等. 黄酮类成分抗肝纤维化作用及其机制的研究进展[J]. 中草药，2022，53（13）：4146-4161.
MA T，KUANG X L，CAI W N，et al. Research progress on effects of flavonoids against hepatic fibrosis and their mechanisms[J]. Chin Tradit Herb Drugs，2022，53（13）：4146-4161.
张敬博，陈平平，于栋华，等. 黄芩-赤芍药对不同比例配伍抗大鼠肝纤维化模型作用机制探讨[J]. 中国实验方剂学杂志，2022，28（12）：69-77.
ZHANG J B，CHEN P P，YU D H，et al. Mechanism of Scutellariae Radix-Paeoniae Radix Rubra combination of different proportions against hepatic fibrosis in rats[J]. Chin J Exp Tradit Med Formulae，2022，28（12）：69-77.
傅柳，严小军，尚广彬，等. 肝纤维化病证结合动物模型的建立及评价方法研究进展[J]. 中华中医药杂志，2022，37（6）：3330-3334.
FU L，YAN X J，SHANG G B，et al. Research progress on establishment and evaluation methods of animal model of hepatic fibrosis disease and syndrome combination[J]. China J Tradit Chin Med Pharm，2022，37（6）：3330-3334.
刘莉，杨静，李宗云，等. 肝爽颗粒对慢性乙型肝炎肝纤维化（S1和S2期）肝郁脾虚兼血瘀证的早期防治疗效[J]. 中国实验方剂学杂志，2022，28（11）：132-138.
LIU L，YANG J，LI Z Y，et al. Ganshuang granule allevia-tes early liver fibrosis（S1 and S2）in chronic hepatitis B with liver depression spleen deficiency and blood stasis syndrome[J]. Chin J Exp Tradit Med Formulae，2022，28（11）：132-138.
杨娇，曹昌娥，赖泳，等. 灯盏花素对张氏肝细胞中CYP3A4和CYP2C19的影响和机制[J]. 中国医院药学杂志，2017，37（16）：1557-1562.
YANG J，CAO C E，LAI Y，et al. Effect of breviscapine on CYP3A4 and CYP2C19 activities and its molecular mechanisms in Chang liver cells[J]. Chin J Hosp Pharm，2017，37（16）：1557-1562.
杨淑艳，钟秀宏，张以忠，等. 灯盏花素对抗结核药致小鼠肝损伤的保护作用及机制研究[J]. 中国药学杂志，2011，46（16）：1242-1244.
YANG S Y，ZHONG X H，ZHANG Y Z，et al. Protective effect of breviscapine on hepatic injury induced by anti-tubercular drugs in mice and its mechanism[J]. Chin Pharm J，2011，46（16）：1242-1244.
张明昊，赵绅，杜婧雯，等. 灯盏花素通过调控TGF-β1介导的Smad和ERK通路干预肾纤维化大鼠的作用机制研究[J]. 中药新药与临床药理，2022，33（10）：1347-1356.
ZHANG M H，ZHAO S，DU J W，et al. Mechanism of breviscapine in intervening renal fibrosis rats through regulating TGF-β1-mediated Smad and ERK pathway[J]. Tradit Chin Drug Res Clin Pharmacol，2022，33（10）：1347-1356.
赵博，彭建军，李广平，等. 灯盏花素通过TGF-β1/Smads通路减轻急性心肌梗死大鼠心室重构[J]. 中国免疫学杂志，2021，37（4）：410-414.
ZHAO B，PENG J J，LI G P，et al. Breviscapine reduces ventricular remodeling in rats with acute myocardial infarction via TGF-β1/Smads pathway[J]. Chin J Immunol，2021，37（4）：410-414.
LI Q，MING Y，JIA H，et al. Poricoic acid A suppresses TGF-β1-induced renal fibrosis and proliferation via the PDGF-C，Smad3 and MAPK pathways[J]. Exp Ther Med，2021，21（4）：289.
许晓刚，张春江，付彦杰，等. 益肾化湿颗粒对MsPGN大鼠肾组织TGF-β1信号通路和ERK1/2磷酸化的影响[J]. 中成药，2023，45（12）：4137-4142.
XU X G，ZHANG C J，FU Y J，et al. Effects of Yishen Huashi Granule on TGF-β1 signal pathway and ERK1/2 phosphorylation in kidney tissue of MsPGN rats[J]. Chin Tradit Pat Med，2023，45（12）：4137-4142.
郑冬晓，陈琳琳，韦其慧，等. 褐藻素通过调控Nrf2/Keap1通路缓解糖尿病大鼠心肌肥大[J]. 南方医科大学学报，2022，42（5）：752-759.
ZHENG D X，CHEN L L，WEI Q H，et al. Fucoxanthin regulates Nrf2/Keap1 signaling to alleviate myocardial hypertrophy in diabetic rats[J]. J South Med Univ，2022，42（5）：752-759.
卢芬萍，胡世平，唐颖慧，等. 丹桃养肝丸对四氯化碳致肝纤维化大鼠的保护作用研究[J]. 现代中西医结合杂志，2023，32（14）：1940-1944，1950.
LU F P，HU S P，TANG Y H，et al. Protective effect of Dantao yanggan pill on carbon tetrachloride induced liver fibrosis in rats[J]. Mod J Integr Tradit Chin West Med，2023，32（14）：1940-1944，1950.
南洋，董辉，王志刚，等. 肝纤维化动物实验模型的研究进展[J]. 中国医药导报，2022，19（12）：34-37.
NAN Y，DONG H，WANG Z G，et al. Research progress of animal experimental model of hepatic fibrosis[J]. China Med Her，2022，19（12）：34-37.
AYDIN M M，AKCALI K C. Liver fibrosis[J]. Turk J Gastroenterol，2018，29（1）：14-21.
孔俊英，王新春. 秋水仙碱对心肌组织中TGF-β1的影响[J]. 哈尔滨医科大学学报，2009，43（6）：552-554.
KONG J Y，WANG X C. Effect of colchicine on myocardium transforming growth factor-beta 1[J]. J Harbin Med Univ，2009，43（6）：552-554.
AWAD A S，ELARINY H A，SALLAM A S. The possible protective effect of colchicine against liver damage induced by renal ischemia-reperfusion injury：role of Nrf2 and NLRP3 inflammasome[J]. Can J Physiol Pharmacol，2020，98（12）：849-854.
MU M，ZUO S，WU R M，et al. Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-β/Smad signaling pathway[J]. Drug Des Devel Ther，2018，12：4107-4115.
PENG Y，LI L，ZHANG X，et al. Fluorofenidone affects hepatic stellate cell activation in hepatic fibrosis by targe-ting the TGF-β1/Smad and MAPK signaling pathways[J]. Exp Ther Med，2019，18（1）：41-48.
TANG N，HONG F，HAO W，et al. Riboflavin ameliorates mitochondrial dysfunction via the AMPK/PGC1α/HO-1 signaling pathway and attenuates carbon tetrachloride- induced liver fibrosis in rats[J]. Exp Ther Med，2022，24（4）：608.
0
Views
2
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.